Consistent with KPT‐330, cleavage of PARP and caspase 3 was strongly enhanced in the combination treatment when compared to ABT‐199 or KPT‐8602 alone in these AML cell lines (Figure 1E). Here, CASP3 is linked to acute myeloid leukemia.